Cargando…

Whole-body Computed Tomography Versus Dual Energy X‑ray Absorptiometry for Assessing Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva

Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic disorder that leads to heterotopic ossification (HO), resulting in progressive restriction of physical function. In this study, low-dose, whole-body computed tomography (WBCT) and dual energy X-ray absorptiometry (DXA) were evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales: Warner, Sarah E., Kaplan, Frederick S., Pignolo, Robert J., Smith, Stacy E., Hsiao, Edward C., De Cunto, Carmen, Di Rocco, Maja, Harnett, Kathleen, Grogan, Donna, Genant, Harry K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531122/
https://www.ncbi.nlm.nih.gov/pubmed/34331548
http://dx.doi.org/10.1007/s00223-021-00877-6
_version_ 1784586788650614784
author Warner, Sarah E.
Kaplan, Frederick S.
Pignolo, Robert J.
Smith, Stacy E.
Hsiao, Edward C.
De Cunto, Carmen
Di Rocco, Maja
Harnett, Kathleen
Grogan, Donna
Genant, Harry K.
author_facet Warner, Sarah E.
Kaplan, Frederick S.
Pignolo, Robert J.
Smith, Stacy E.
Hsiao, Edward C.
De Cunto, Carmen
Di Rocco, Maja
Harnett, Kathleen
Grogan, Donna
Genant, Harry K.
author_sort Warner, Sarah E.
collection PubMed
description Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic disorder that leads to heterotopic ossification (HO), resulting in progressive restriction of physical function. In this study, low-dose, whole-body computed tomography (WBCT) and dual energy X-ray absorptiometry (DXA) were evaluated to determine the preferred method for assessing total body burden of HO in patients with FOP. This was a non-interventional, two-part natural history study in patients with FOP (NCT02322255; date of registration: December 2014). In Part A (described here), WBCT and DXA scans were individually assessed for HO presence and severity across 15 anatomical regions. All images were independently reviewed by an expert imaging panel. Ten adult patients were enrolled across four sites. The sensitivity to HO presence and severity varied considerably between the two imaging modalities, with WBCT demonstrating HO in more body regions than DXA (76/138 [55%] versus 47/113 [42%]) evaluable regions). Inability to evaluate HO presence, due to overlapping body regions (positional ambiguity), occurred less frequently by WBCT than by DXA (mean number of non-evaluable regions per scan 1.2 [standard deviation: 1.5] versus 2.4 [1.4]). Based on the increased sensitivity and decreased positional ambiguity of low-dose WBCT versus DXA in measuring HO in patients with FOP, low-dose WBCT was chosen as the preferred imaging for measuring HO. Therefore, low-dose WBCT was carried forward to Part B of the natural history study, which evaluated disease progression over 36 months in a larger population of patients with FOP.
format Online
Article
Text
id pubmed-8531122
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-85311222021-11-04 Whole-body Computed Tomography Versus Dual Energy X‑ray Absorptiometry for Assessing Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva Warner, Sarah E. Kaplan, Frederick S. Pignolo, Robert J. Smith, Stacy E. Hsiao, Edward C. De Cunto, Carmen Di Rocco, Maja Harnett, Kathleen Grogan, Donna Genant, Harry K. Calcif Tissue Int Original Research Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic disorder that leads to heterotopic ossification (HO), resulting in progressive restriction of physical function. In this study, low-dose, whole-body computed tomography (WBCT) and dual energy X-ray absorptiometry (DXA) were evaluated to determine the preferred method for assessing total body burden of HO in patients with FOP. This was a non-interventional, two-part natural history study in patients with FOP (NCT02322255; date of registration: December 2014). In Part A (described here), WBCT and DXA scans were individually assessed for HO presence and severity across 15 anatomical regions. All images were independently reviewed by an expert imaging panel. Ten adult patients were enrolled across four sites. The sensitivity to HO presence and severity varied considerably between the two imaging modalities, with WBCT demonstrating HO in more body regions than DXA (76/138 [55%] versus 47/113 [42%]) evaluable regions). Inability to evaluate HO presence, due to overlapping body regions (positional ambiguity), occurred less frequently by WBCT than by DXA (mean number of non-evaluable regions per scan 1.2 [standard deviation: 1.5] versus 2.4 [1.4]). Based on the increased sensitivity and decreased positional ambiguity of low-dose WBCT versus DXA in measuring HO in patients with FOP, low-dose WBCT was chosen as the preferred imaging for measuring HO. Therefore, low-dose WBCT was carried forward to Part B of the natural history study, which evaluated disease progression over 36 months in a larger population of patients with FOP. Springer US 2021-07-31 2021 /pmc/articles/PMC8531122/ /pubmed/34331548 http://dx.doi.org/10.1007/s00223-021-00877-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Research
Warner, Sarah E.
Kaplan, Frederick S.
Pignolo, Robert J.
Smith, Stacy E.
Hsiao, Edward C.
De Cunto, Carmen
Di Rocco, Maja
Harnett, Kathleen
Grogan, Donna
Genant, Harry K.
Whole-body Computed Tomography Versus Dual Energy X‑ray Absorptiometry for Assessing Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva
title Whole-body Computed Tomography Versus Dual Energy X‑ray Absorptiometry for Assessing Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva
title_full Whole-body Computed Tomography Versus Dual Energy X‑ray Absorptiometry for Assessing Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva
title_fullStr Whole-body Computed Tomography Versus Dual Energy X‑ray Absorptiometry for Assessing Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva
title_full_unstemmed Whole-body Computed Tomography Versus Dual Energy X‑ray Absorptiometry for Assessing Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva
title_short Whole-body Computed Tomography Versus Dual Energy X‑ray Absorptiometry for Assessing Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva
title_sort whole-body computed tomography versus dual energy x‑ray absorptiometry for assessing heterotopic ossification in fibrodysplasia ossificans progressiva
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531122/
https://www.ncbi.nlm.nih.gov/pubmed/34331548
http://dx.doi.org/10.1007/s00223-021-00877-6
work_keys_str_mv AT warnersarahe wholebodycomputedtomographyversusdualenergyxrayabsorptiometryforassessingheterotopicossificationinfibrodysplasiaossificansprogressiva
AT kaplanfredericks wholebodycomputedtomographyversusdualenergyxrayabsorptiometryforassessingheterotopicossificationinfibrodysplasiaossificansprogressiva
AT pignolorobertj wholebodycomputedtomographyversusdualenergyxrayabsorptiometryforassessingheterotopicossificationinfibrodysplasiaossificansprogressiva
AT smithstacye wholebodycomputedtomographyversusdualenergyxrayabsorptiometryforassessingheterotopicossificationinfibrodysplasiaossificansprogressiva
AT hsiaoedwardc wholebodycomputedtomographyversusdualenergyxrayabsorptiometryforassessingheterotopicossificationinfibrodysplasiaossificansprogressiva
AT decuntocarmen wholebodycomputedtomographyversusdualenergyxrayabsorptiometryforassessingheterotopicossificationinfibrodysplasiaossificansprogressiva
AT diroccomaja wholebodycomputedtomographyversusdualenergyxrayabsorptiometryforassessingheterotopicossificationinfibrodysplasiaossificansprogressiva
AT harnettkathleen wholebodycomputedtomographyversusdualenergyxrayabsorptiometryforassessingheterotopicossificationinfibrodysplasiaossificansprogressiva
AT grogandonna wholebodycomputedtomographyversusdualenergyxrayabsorptiometryforassessingheterotopicossificationinfibrodysplasiaossificansprogressiva
AT genantharryk wholebodycomputedtomographyversusdualenergyxrayabsorptiometryforassessingheterotopicossificationinfibrodysplasiaossificansprogressiva